Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2 studies found for:    Open Studies | Heart Defects Congenital | UCSD OR UC San Diego OR VA San Diego
Show Display Options
Rank Status Study
1 Recruiting Nit-Occlud PDA Post-Approval Study
Condition: Patent Ductus Arteriosus (PDA)
Intervention:
2 Recruiting MAESTRO (Macitentan in Eisenmenger Syndrome To Restore Exercise Capacity)
Condition: Eisenmenger Syndrome
Interventions: Drug: Macitentan 10 mg, oral tablet, to be taken once daily.;   Drug: Matching placebo oral tablet, to be taken once daily.

Indicates status has not been verified in more than two years